Jump to content
×
×
  • Create New...

Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis


Recommended Posts

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.

 

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

§  A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies. 

§  An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).

§  An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).

§  Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).

§  A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.

§  A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.

§  A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.

§  A discussion on various steps involved in development operations of companion diagnostics

§  A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of test

§  Laboratory Developed Tests (LDTs)

§  Companion Diagnostic Tests (CDx)

§  Type of disease indication

§  Breast cancer

§  Blood cancer

§  Colon / Colorectal cancer

§  Lung Cancer

§  Melanoma

§  Prostate Cancer

§  Type of cancer biomarker

§  TMB

§  MSI / MMR

§  TILs

§  Type of analytical technique

§  Next Generation Sequencing (NGS)

§  Polymerase Chain Reaction (PCR)

§  Immunohistochemistry (IHC)

§  Others

 

§  Key geographical regions

§  North America

§  Europe

§  Japan

§  China

§  Australia 

 

Key companies covered in the report

§  Foundation Medicine

§  NeoGenomics Laboratories

§  Novogene

§  Q2 Solutions

§  Personal Genome Diagnostics

§  Dr Lal PathLabs

§  Shenzhen Yuce Biotechnology

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html

 

Other Recent Offerings

1.     Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030

2.     Neoantigen Targeted Therapies Market, 2019-2030

3.     Companion Diagnostics Market (2nd Edition), 2019-2030

4.     Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

5.     In Vitro ADME Testing Services Market, 2019-2030

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    No registered users viewing this page.


    Administrador |  Diretor |  Coordenador |  Moderador |  Suporter |  Estagiário |  Herói
  • Similar Content

    • By Steffan Joe
      Owing to their cost and time saving potential, in silico tools are widely used in modern pharmacological research; several companies have developed novel tools, which are specifically designed to accelerate and augment the drug discovery process.
       
       
      Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.
       
      Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.
       
      To order this 290+ page report, which features 120+ figures and 130+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html
       
      Key Market Insights
       
      Over 90 players currently claim to provide In Silico drug discovery services for biologics
      More than 70% of these are small and mid-sized firms. Further, close to 60% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes. It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services
       
      Over 150 software solutions are currently available for use in drug discovery
      Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery. Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.
       
      Nearly 80% of in silico drug discovery service providers are based in the developed geographies
      This can be attributed to the relatively high adoption of the In Silico approach by players based in Europe and North America. On the other hand, there are companies that are using this approach for drug discovery operations, in emerging regions, such as India and China, as well.
       
      Around 40% of the companies claim to specialize in antibodies, proteins and peptides
      Within the antibodies segment, nearly 60% of In Silico service offerings are focused on the discovery of monoclonal antibodies. This is followed by companies providing services for antibody fragments (43%), bispecific antibodies (34%) and polyclonal antibodies (26%).
       
       
      To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/298/request-sample.html
       
      Key Questions Answered
      §  Who are the leading in silico service providers for discovery of different types of large molecule drugs?
      §  What are the key challenges associated with the discovery of large molecule drugs?
      §  What is the likely cost saving opportunity associated with the use of in silico tools?
      §  What are the key computational approaches being used by in silico service providers for drug discovery operations?
      §  What are the popular business strategies being used by in silico drug discovery service providers?
      §  How is the current and future market opportunity likely to be distributed across key market segments?
       
      The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments:
      §  Key Drug Discovery Steps
      §  Target Identification
      §  Target Validation
      §  Hit Generation
      §  Hit-to-Lead
      §  Lead Optimization 
       
      §  Type of Large Molecule
      §  Antibodies
      §  Proteins
      §  Peptides
      §  Nucleic Acids
      §  Vectors
       
      §  Company Size
      §  Small
      §  Mid-sized
      §  Large
       
      §  Target therapeutic Area
      §  Autoimmune Disorders
      §  Blood Disorders
      §  Cardiovascular Disorders
      §  Gastrointestinal and Digestive Disorders
      §  Hormonal Disorders
      §  Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
      §  Infectious Diseases
      §  Metabolic Disorders
      §  Mental Disorders
      §  Musculoskeletal Disorders
      §  Neurological Disorders
      §  Oncological Disorders
      §  Respiratory Disorders
      §  Skin Disorders
      §  Urogenital Disorders
      §  Others
       
      §  Type of Sponsor
      §  Industry Players
      §  Non-Industry Players
       
      §  Key Geographical Regions
      §  North America
      §  Europe
      §  Asia-Pacific
       
      The report features inputs from eminent industry stakeholders, according to whom the in silico approaches significantly simplifies the drug discovery process, offering better screening accuracy, as well as enabling innovators to reduce wet-lab efforts. The report includes detailed transcripts of discussions held with the following experts:
      §  John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
      §  Sven Benson (Founder, candidum)
      §  Mark Whittaker (Senior Vice President, Evotec)
      §  Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
       
      The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), in silico-based service(s) portfolio and an informed future outlook.
      §  Abzena
      §  BioDuro
      §  BioNTech
      §  ChemPartner
      §  Creative Biostructure
      §  GenScript
      §  LakePharma
      §  Sundia MediTech
      §  Sygnature Discovery
      §  Viva Biotech
       
      For additional details, please visit 
      https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html or email sales@rootsanalysis.com
       
      You may also be interested in the following titles:
      1.     DNA-Encoded Libraries: Platforms and Services Market
      2.     Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
      3.     Companion Diagnostics Services Market, 2020-2030
       
      About Roots Analysis
      Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
       
      Contact Information
      Roots Analysis Private Limited
      Gaurav Chaudhary
      +1 (415) 800 3415
      ben.johnson@rootsanalysis.com
      Facebook - https://www.facebook.com/RootsAnalysis
      LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
      Twitter - https://twitter.com/RootsAnalysis
    • By Steffan Joe
      Drug discovery is challenging and involves several complexities. In order to continue to add new molecules their pipelines, drug developers are opting to outsource such operations to contract research organizations (CROs). Outsourcing of peptides and macrocycle drug discovery has emerged as one of the recent trends in the overall pharmaceutical domain.
       
      To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html
       
      The USD 1.5 billion (by 2030) financial opportunity within the peptides and macrocycles drug discovery service and platform providers market has been analyzed across the following segments:
      §  Type of peptides
      §  Synthetic peptides
      §  Biologic and recombinant peptides
       
      §  Type of discovery steps
      §  Target identification and validation
      §  Hit identification
      §  Lead generation
      §  Lead optimization
       
      §  Therapeutic Area
      §  Oncological disorders
      §  Metabolic disorders
      §  Cardiovascular disorders
      §  Infectious diseases
      §  Urological disorders
      §  Endocrine disorders
      §  CNS disorders
      §  Other diseases
       
      To request for sample report - https://www.rootsanalysis.com/reports/303/request-sample.html
       
      §  Company Size
      §  Small companies
      §  Mid-sized companies
      §  Large and very large companies
       
      §  Key geographical regions
      Europe North America Asia-Pacific and the Rest of the World  
      The report features inputs from eminent industry stakeholders, according to whom peptide and macrocycles drug discovery outsourcing market is continuously pacing up. The report includes detailed transcripts of discussions held with the following experts:
      §  Mark I Peterson (CEO, Cyclenium Pharma)
      §  Jan Hoflack (Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)
      The research covers profiles of key players that offer peptides and macrocyclic drugs discovery platforms and services, featuring an overview of the company, its service portfolio / technology platform, and an informed future outlook.
      §  GenScript
      §  JPT Peptide Technologies
      §  CPC Scientific
      §  IRBM
      §  Creative Peptides
      §  Pepscan
      §  Interprotein
      §  RA Pharmaceuticals
      §  Pepticom
      §  PeptiDream
      §  Creative Biolabs
      §  MeSCue-Janusys
       
      Table of Contents
       
      1. Preface

      2. Executive Summary

      3. Introduction
       
      4. Market Landscape of Service Providers
       
      5. Benchmark Analysis
       
      6. Market Landscape of Platform Providers
       
      7. Company Profiles
       
      8. Partnerships
       
      9. Market Forecast and Opportunity Analysis
       
      10. SWOT Analysis
       
      11. Conclusion
       
      12. Executive Insights
       
      13. Appendix 1: List of Companies and Organizations
       
      14. Appendix 1: Tabulated Data
       
       
      To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
      About Roots Analysis
      Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
       
      Contact Information
      Roots Analysis Private Limited
      Gaurav Chaudhary
      +1 (415) 800 3415
      ben.johnson@rootsanalysis.com
      Facebook - https://www.facebook.com/RootsAnalysis
      LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
      Twitter - https://twitter.com/RootsAnalysis
    • By kevin987
      STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies
       
      Roots Analysis is pleased to announce the publication of its recent study, titled, “STING Pathway Targeting Therapeutics and Technologies, 2020-2030.”
       
      The report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
      §  A detailed assessment of the current market landscape of therapeutics targeting STING Pathway. 
      §  A detailed assessment of the current market landscape of various technology platforms that are being actively used for the development of STING modulators.
      §  Detailed profiles of developers of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products).
      §  An in-depth analysis of more than 280 grants that have been awarded to research institutes engaged in STING pathway targeting therapeutics-related projects.
      §  An analysis of the initiatives of big pharma players engaged in this domain.
      §  An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of STING pathway targeting therapeutics.
      §  A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020.
      §  An analysis of the partnerships that have been established in this domain, in the recent past.
      §  An analysis of the investments made in this domain.
      §  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
      §  Types of Payment
      §  Upfront Payments
      §  Milestone Payments
       
      §  Type of STING Modulator
      §  Agonist
      §  Antagonist
       
      §  Key Therapeutic Area(s)
      §  Oncological Disorders
      §  Inflammatory Disorders
      §  Infectious Diseases
      §  Others
       
      §  Route of Administration
      §  Intratumoral
      §  Intravenous
      §  Oral
      §  Subcutaneous
      §  Others
       
      §  Type of Molecule
      §  Non-nucleotide
      §  Cyclic Dinucleotide
      §  Live Biotherapeutics
      §  Oncolytic Peptides
      §  Synthetic Peptides
      §  Others
       
      §  Key Geographical Regions
      §  North America
      §  Europe
      §  Asia-Pacific
       
      Key companies covered in the report
      §  Aduro Biotech
      §  Bristol Myers Squibb
      §  Eisai
      §  GlaxoSmithKline
      §  ImmuneSensor Therapeutics
      §  Merck
      §  Noxopharm
      §  Spring Bank Pharmaceuticals
      §  Synlogic
       
      For more information please click on the following link:
      https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
       
      Other Recent Offerings
      1.       Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030
      2.     Global Psychedelic Therapeutics Market by Type of Psychedelic Substance (Ketamine, Psilocybin, MDMA and Others), by Origin (Natural and Synthetic), by Type of Therapy (Monotherapy, Combination and Others), by Route of Administration (Oral, Intravenous, Intranasal and Others) and by Key Geographies (North America, Europe and Asia- Pacific and rest of the world): Industry Trends and Global Forecasts, 2020-2030
      3.     Endocannabinoid System Targeted Therapeutics Market, 2020-2030
       
       
      About Roots Analysis
      Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
       
      Contact Information
      Roots Analysis Private Limited
      Gaurav Chaudhary
      +1 (415) 800 3415
      ben.johnson@rootsanalysis.com
      Facebook - https://www.facebook.com/RootsAnalysis
      LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
      Twitter - https://twitter.com/RootsAnalysis
       
    • By kevin987
      Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
       
      To order this 330+ page report, which features 130+ figures and 145+ tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
       
      Key Market Insights
      §  More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts
      §  The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes
      §  Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain
      §  Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
      §  A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts
      §  Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs
      §  Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014
      §  The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies
      §  Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs
      §  As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions
       
      For more information please visit:
      https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
       
      Table of Contents
       
      1.                     PREFACE
      1.1.                   Scope of the Report
      1.2.                   Research Methodology
      1.3.                   Chapter Outlines

      2.                     EXECUTIVE SUMMARY
       
      3.                     INTRODUCTION
      3.1.                   Context and Background
      3.2.                   Concept of Protein Homeostasis
      3.3.                   Discovery of the Ubiquitin Proteasome System
      3.3.1.                Ubiquitin: Structure and Function
      3.3.2.                Fundamentals of the UPS
      3.3.3.                Components of the UPS
       
      3.4.                   Key Steps Involved in the UPS
      3.4.1.                Ubiquitination: The First Step
      3.4.2.                Proteasomal Degradation: The Second Step
       
      3.5.                   Therapeutic Applications of the UPS
      3.6.                   Advantages and Challenges Associated with Ubiquitin Enzyme Inhibitors
      3.7.                   Targeted Protein Degradation: Enhancing Ubiquitination to Degrade Undruggable Targets
      3.7.1.                Brief History of Targeted Protein Degradation
       
      3.8.                   Types of Protein Degraders
      3.8.1.                Selective Hormone Receptor Degraders (SHRDs)
      3.8.2.                Immumodulatory Imide Drugs (IMiDs)
      3.8.3.                PROTACs
      3.8.4.                Other Chimeras (ENDTACs, LYTACs and PHOTACs)
      3.8.4.1.             Endosome Targeting Chimeras (ENDTACs)
      3.8.4.2.             Lysozyme targeting chimeras (LYTACs)
      3.8.5.                Specific and Nongenetic Inhibitor-of-Apoptosis Proteins (IAP)-dependent Protein Erasers (SNIPERS)
      3.8.6.                Hydrophobic Tag
      3.8.7.                Molecular Glues
      3.8.8.                DUB Inhibitors  
       
      3.9.                   Growth Drivers and Roadblocks
       
      4.                     CURRENT MARKET LANDSCAPE
      4.1.                   Chapter Overview
      4.2.                   Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
      4.2.1.                Analysis by Type of Protein Degrader
      4.2.2.                Analysis by Phase of Development
      4.2.3.                Analysis by Therapeutic Area
      4.2.4.                Analysis by Target Indication
      4.2.5.                Analysis by Type of Target Enzyme
      4.2.6.                Analysis by Type of Target Protein
      4.2.7.                Analysis by Type of Therapy
      4.2.8.                Analysis by Route of Administration
       
      4.3.                   Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
       
      4.4.                   Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
      4.4.1.                Analysis by Year of Establishment
      4.4.2.                Analysis by Location of Headquarters
      4.4.3.                Analysis by Size of Company
      4.4.4.                Analysis by Type of Protein Degrader
       
      5.                     COMPANY PROFILES
      5.1.                   Chapter Overview
      5.2.                   Developers with Clinical Candidates
      5.2.1.                Radius Health
      5.2.1.1.             Company Overview
      5.2.1.2.             Targeted Protein Degradation-based Drug Portfolio
      5.2.1.2.1.          Product Description: Elacestrant
      5.2.1.3.             Recent Developments and Future Outlook
       
      5.2.2.                Celgene
      5.2.2.1.             Company Overview
      5.2.2.2.             Financial Information
      5.2.2.3.             Targeted Protein Degradation-based Drug Portfolio
      5.2.2.3.1.          Avadomide (CC-122)
      5.2.2.3.2.          Iberdomide (CC-220)
      5.2.2.4.             Recent Developments and Future Outlook
       
      5.2.3.                Sanofi Genzyme
      5.2.3.1.             Company Overview
      5.2.3.2.             Financial Information
      5.2.3.3.             Targeted Protein Degradation-based Drug Portfolio
      5.2.3.3.1.          Product Description: SAR439859
      5.2.3.4.             Recent Developments and Future Outlook
       
       
      About Roots Analysis
      Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
       
      Contact Information
      Roots Analysis Private Limited
      Gaurav Chaudhary
      +1 (415) 800 3415
      ben.johnson@rootsanalysis.com
      Facebook - https://www.facebook.com/RootsAnalysis
      LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
      Twitter - https://twitter.com/RootsAnalysis